Jill Howe
Directeur Financier/CFO chez LINEAGE CELL THERAPEUTICS, INC.
Fortune : 3 266 $ au 30/04/2024
Profil
Jill Ann Howe is currently the Director at MUSC Foundation for Research Development.
She also holds current positions as an Independent Director at Biora Therapeutics, Inc., a Director at Codagenix, Inc., and the Chief Financial Officer at Lineage Cell Therapeutics, Inc. In her former roles, Ms. Howe served as the Finance Director & Controller at Somaxon Pharmaceuticals, Inc. and Receptos LLC.
She was also the Finance Director & Controller at Amplyx Pharmaceuticals, Inc. from 2016 to 2017.
Additionally, she held the position of Chief Financial Officer at DTx Pharma, Inc. from 2021 to 2022, and Treasurer & VP-Finance at Gossamer Bio, Inc. from 2018 to 2021.
Ms. Howe obtained her undergraduate degree from San Diego State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIORA THERAPEUTICS, INC.
0,01% | 01/03/2024 | 5 381 ( 0,01% ) | 3 266 $ | 30/04/2024 |
Postes actifs de Jill Howe
| Sociétés | Poste | Début |
|---|---|---|
| BIORA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 03/11/2021 |
| LINEAGE CELL THERAPEUTICS, INC. | Directeur Financier/CFO | 14/11/2022 |
Codagenix, Inc.
 Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | Directeur/Membre du Conseil | 06/10/2021 |
| MUSC Foundation for Research Development | Directeur/Membre du Conseil | - |
Anciens postes connus de Jill Howe
| Sociétés | Poste | Fin |
|---|---|---|
DTx Pharma, Inc.
 DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | Directeur Financier/CFO | 01/07/2022 |
| GOSSAMER BIO, INC. | Treasurer | 01/06/2021 |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Directeur Financier/CFO | 01/12/2017 |
Somaxon Pharmaceuticals, Inc.
 Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | Directeur Financier/CFO | - |
| RECEPTOS INC | Directeur Financier/CFO | - |
Formation de Jill Howe
| San Diego State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIORA THERAPEUTICS, INC. | Health Services |
| GOSSAMER BIO, INC. | Health Technology |
| LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
DTx Pharma, Inc.
DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | Health Technology |
Codagenix, Inc.
Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | Health Services |
| MUSC Foundation for Research Development | |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Health Technology |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | Health Technology |
